In November 2007, the Company met a milestone under the license agreement with Novartis
for iloperidone relating to the acceptance of the NDA
for iloperidone in schizophrenia and made a license payment of $ 5.0 million to Novartis.
In connection with this goal, Vanda's management team has been working diligently over the past several months with the Food & Drug Administration («FDA») to reevaluate its response to Vanda's New Drug Application («NDA»)
for iloperidone for the treatment of schizophrenia.
Not exact matches
TCP's withdrawal of its nominations and stockholder proposal follows Vanda's announcement that the U.S. Food & Drug Administration had granted marketing approval of its product, Fanapt ™ (
iloperidone),
for the acute treatment of adult patients with schizophrenia.